CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides
- PMID: 6249192
- PMCID: PMC283841
- DOI: 10.1128/AAC.17.4.615
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides
Abstract
CP-45,899 is a new, semisynthetic beta-lactamase inhibitor. When tested alone, CP-45,899 displayed only weak antibacterial activity, with the notable exception of its potent action against penicillin-susceptible and -resistant Neisseria gonorrhoeae. A combination of 3.12 microgram of CP-45,899 per ml with 3.12 microgram of ampicillin per ml, tested in broth cultures, inhibited ca. 90% of resistant Staphylococcus and Haemophilus influenzae strains; similar data were obtained in a variety of media. The same combination of CP-45,899 with ampicillin or penicillin G inhibited 90% of Bacteroides fragilis as interpreted from agar dilution minimal inhibitory concentrations. Inhibitory concentrations of CP-45,899-ampicillin were bactericidal against H. influenzae strains and were as bactericidal as nafcillin or cephalothin against S. aureus. Ampicillin-resistant S. aureus, H. influenzae, and B. fragilis strains did not develop resistance to CP-45,899-ampicillin when transferred as many as six passages in the presence of a sublethal concentration of the combination.
Similar articles
-
6 beta-Iodopenicillanic acid (UI-38,006), a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactam compounds: initial bacteriological characterization.Antimicrob Agents Chemother. 1981 Sep;20(3):327-31. doi: 10.1128/AAC.20.3.327. Antimicrob Agents Chemother. 1981. PMID: 6272628 Free PMC article.
-
Synergistic action of ampicillin and nafcillin against ampicillin-resistant Haemophilus influenzae.Antimicrob Agents Chemother. 1980 Mar;17(3):461-3. doi: 10.1128/AAC.17.3.461. Antimicrob Agents Chemother. 1980. PMID: 6968540 Free PMC article.
-
Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S528-34. doi: 10.1093/clinids/8.supplement_5.s528. Rev Infect Dis. 1986. PMID: 3026001
-
Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S300-15. doi: 10.1093/clinids/4.supplement_2.s300. Rev Infect Dis. 1982. PMID: 6294779 Review.
-
Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.Drugs. 1987 Jun;33(6):577-609. doi: 10.2165/00003495-198733060-00003. Drugs. 1987. PMID: 3038500 Review.
Cited by
-
Drug repurposing screens and synergistic drug-combinations for infectious diseases.Br J Pharmacol. 2018 Jan;175(2):181-191. doi: 10.1111/bph.13895. Epub 2017 Jul 9. Br J Pharmacol. 2018. PMID: 28685814 Free PMC article. Review.
-
Sulbactam/ampicillin for treatment of polymicrobial pelvic infections.Drugs. 1986;31 Suppl 2:22-5. doi: 10.2165/00003495-198600312-00006. Drugs. 1986. PMID: 3013569 Clinical Trial.
-
Evaluation of three 4"-deoxy-4"-sulfonamido-oleandomycin derivatives with erythromycin-like antibacterial potency.Antimicrob Agents Chemother. 1984 Jan;25(1):118-22. doi: 10.1128/AAC.25.1.118. Antimicrob Agents Chemother. 1984. PMID: 6703675 Free PMC article.
-
In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.Antimicrob Agents Chemother. 1985 May;27(5):876-8. doi: 10.1128/AAC.27.5.876. Antimicrob Agents Chemother. 1985. PMID: 2990330 Free PMC article.
-
Therapeutic trial and pharmacokinetics of sulbactam for uncomplicated gonorrhea in men.Antimicrob Agents Chemother. 1984 Nov;26(5):683-5. doi: 10.1128/AAC.26.5.683. Antimicrob Agents Chemother. 1984. PMID: 6097173 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous